Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In
the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple …

We evaluated HLA-compatible donor leukocyte infusions (DLIs) and HLA-compatible or HLA-disparate
EBV-specific T cells (EBV-CTLs) in 49 hematopoietic cell transplantation …

Antibiotic treatment can deplete the commensal bacteria of a patient’s gut microbiota and,
paradoxically, increase their risk of subsequent infections. In allogeneic hematopoietic stem …

Cellular therapy of Epstein-Barr virus (EBV) + posttransplantation lymphoproliferative diseases
(PTLD) in cord blood transplant (CBT) recipients is limited by lack of donor access and …

New technologies are needed to characterize the migration, survival, and function of antigen-specific
T cells in vivo. Here, we demonstrate that Epstein-Barr virus (EBV)–specific T cells …

In contrast to the upfront setting in which the role of high-dose therapy with autologous
hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with …

Delays in immune recovery after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
are associated with increased risks of infection and relapse. IL-7 has a central role in T-…

BACKGROUND Adoptive transfer of donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTLs)
can eradicate EBV-associated lymphomas (EBV-PTLD) after transplantation of …

Adoptive immunotherapy with transplant donor-derived virus-specific T cells has emerged
as a potentially curative approach for the treatment of drug-refractory EBV+ lymphomas as …

Background Refractory CMV viremia and disease are associated with significant morbidity
and mortality in recipients of hematopoietic stem cell transplant (HCT). Methods In phase I/II …